Skip to content
Search

Latest Stories

Market Exit: PCSE takes over administration of pharmacy premises withdrawal

Market Exit: PCSE takes over administration of pharmacy premises withdrawal

Any pharmacy premises withdrawal requests submitted before 1st July 2024 will still be processed directly by the respective integrated care board  

From today, Primary Care Support England (PCSE) will manage the administration and processing of notices of withdrawal from a pharmaceutical list.


Pharmacy and dispensing appliance contractors who wish to withdraw their premises must now submit closure notification forms to PCSE, which will forward them to the relevant integrated care board (ICB).

Withdrawal notices should be sent to pcse.marketentry@nhs.net.

NHS England announced PCSE's new role last week.

For permanent closure of premises, pharmacies with 40 core opening hours, those with more than 40 core opening hours under a direction, and dispensing appliance contractors are required to give a minimum notice period of three months.

Pharmacies that operate or have operated under the 100-hour condition must provide at least six months' notice.

Under regulation 67 of the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013, as amended, if it is impracticable for contractors to provide the required notice period, they must inform NHS England (or the ICB in whose area the premises are located from 1 April 2023) as soon as it is practicable to do so.

Additionally, the ICB can agree to a shorter notice period.

Closure of premises notification should be completed by contractors where they wish to withdraw premises from a pharmaceutical list. This form is not applicable to contractors operating under a local pharmaceutical services (LPS) contract or dispensing doctors looking to withdraw premises from a dispensing doctor list.

Any withdrawal requests submitted before 1 July 2024 will still be processed directly by the ICB, and any related inquiries should be addressed to the respective ICB.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less